Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 12:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 307 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Tenofovir Disoproxil Fumarate Clear all
Completed Phase 1 Interventional

Safety of Tenofovir Disoproxil Fumarate (TDF) and Emtricitabine/TDF in HIV Infected Pregnant Women and Their Infants

NCT00076791
View directory record Official record
Conditions
HIV Infections
Interventions
Emtricitabine/Tenofovir disoproxil fumarate, Tenofovir disoproxil fumarate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older · Female only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
11
States / cities
Washington D.C., District of Columbia • Miami, Florida • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 8, 2026, 12:37 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of Switching to Tenofovir Alafenamide (TAF) From Tenofovir Disoproxil Fumarate (TDF) and/or Other Oral Antiviral Treatment (OAV)

NCT03180619
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
TAF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
4
States / cities
Los Angeles, California • San Jose, California • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2021 · Synced Oct 8, 2026, 12:37 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults

NCT02603107
View directory record Official record
Conditions
HIV-1 Infection
Interventions
RTV, ATV, DRV, COBI, ATV/co, DRV/co, FTC/TDF, ABC/3TC, B/F/TAF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
578 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
63
States / cities
Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 49 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2020 · Synced Oct 8, 2026, 12:37 PM EDT
Completed Not applicable Interventional

Effect of Tenofovir Disoproxil Fumarate on Lipid Levels in HIV Infected Adults on Stable Anti-HIV Drug Therapy

NCT00109603
View directory record Official record
Conditions
HIV Infections, Dyslipidemia, Hyperlipidemia, Hypercholesterolemia, Hypertriglyceridemia
Interventions
Tenofovir disoproxil fumarate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
19
States / cities
Los Angeles, California • San Diego, California • Denver, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2012 · Synced Oct 8, 2026, 12:37 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

The ADAPT Study: Use of Emtricitabine and Tenofovir Disoproxil Fumarate for Pre-Exposure Prophylaxis (PrEP)

NCT01327651
View directory record Official record
Conditions
HIV Infections
Interventions
Daily dosing, Time-driven dosing, Event-driven dosing
Drug
Lead sponsor
HIV Prevention Trials Network
Network
Eligibility
18 Years and older
Enrollment
622 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 27, 2025 · Synced Oct 8, 2026, 12:37 PM EDT
Completed Phase 2 Interventional Results available

Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen

NCT01400412
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Darunavir, Ritonavir, Tenofovir disoproxil fumarate, Emtricitabine, Placebo for Tenofovir disoproxil fumarate, Placebo for Maraviroc, Maraviroc
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
37
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 8, 2026, 12:37 PM EDT
Completed Phase 3 Interventional Results available

Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Adults Who Are Virologically Suppressed

NCT03110380
View directory record Official record
Conditions
HIV-1-infection
Interventions
B/F/TAF, F/TAF, DTG, DTG Placebo, F/TAF Placebo, B/F/TAF Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
567 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
66
States / cities
Phoenix, Arizona • Los Angeles, California • Oakland, California + 47 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2022 · Synced Oct 8, 2026, 12:37 PM EDT
Completed Phase 4 Interventional Results available

A Demonstration Project to Add Pre- or Post-exposure Prophylaxis to Combination HIV Prevention Services

NCT01781806
View directory record Official record
Conditions
HIV Prevention
Interventions
emtricitabine 200mg/tenofovir 300mg
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older · Male only
Enrollment
328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 6, 2018 · Synced Oct 8, 2026, 12:37 PM EDT
Completed Phase 4 Interventional Results available

Immune Reconstitution as a Determinant of Adverse Effects to New Antiretroviral Therapy in Persons With Advanced HIV Infection

NCT00885664
View directory record Official record
Conditions
HIV Infections
Interventions
Truvada (tenofovir/emtricitabine), Kaletra (lopinavir/ritonavir)
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 10, 2022 · Synced Oct 8, 2026, 12:37 PM EDT
Completed Phase 3 Interventional Results available

Comparative Study of Three NNRTI-Sparing HAART Regimens

NCT00811954
View directory record Official record
Conditions
HIV Infection
Interventions
Emtricitabine/tenofovir disoproxil fumarate, Raltegravir, Darunavir, Ritonavir, Atazanavir
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
1,814 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
55
States / cities
Birmingham, Alabama • Long Beach, California • Los Angeles, California + 39 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2014 · Synced Oct 8, 2026, 12:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Examining Hair to Determine Tenofovir Exposure

NCT00903084
View directory record Official record
Conditions
HIV
Interventions
Tenofovir Disoproxil Fumarate
Drug
Lead sponsor
Public Health Foundation Enterprises, Inc.
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Oct 8, 2026, 12:37 PM EDT
Completed Phase 1 Interventional Results available

Body Compartment PK for New HIV Pre-exposure Prophylaxis Modalities

NCT02985996
View directory record Official record
Conditions
HIV Infections
Interventions
Truvada, Genvoya
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 49 Years · Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Oct 8, 2026, 12:37 PM EDT
Completed Phase 2 Interventional Results available

D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults

NCT01565850
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, HIV Infections
Interventions
D/C/F/TAF, DRV, COBI, FTC/TDF, D/C/F/TAF Placebo, DRV Placebo, COBI Placebo, FTC/TDF Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
43
States / cities
Birmingham, Alabama • Beverly Hills, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2016 · Synced Oct 8, 2026, 12:37 PM EDT
Completed Not applicable Interventional Results available

Safety and Effectiveness of Short-Term Anti-HIV Drug Therapy for Recent HIV-1 Infection

NCT00414518
View directory record Official record
Conditions
HIV Infections
Interventions
Tenofovir disoproxil fumarate/Emtricitabine, Lopinavir/Ritonavir
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Denver, Colorado • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 20, 2013 · Synced Oct 8, 2026, 12:37 PM EDT
Completed Phase 3 Interventional Results available

An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)

NCT02831673
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus, HIV Infections
Interventions
Dolutegravir (DTG), Lamivudine (3TC), Tenofovir disoproxil fumarate/Emtricitabine (TDF/FTC FDC)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
719 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
15
States / cities
Phoenix, Arizona • Washington D.C., District of Columbia • Ft. Pierce, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2023 · Synced Oct 8, 2026, 12:37 PM EDT
Completed Phase 1 Interventional

Raltegravir as Early Therapy in African-Americans Living With HIV Study

NCT00667433
View directory record Official record
Conditions
HIV Infections
Interventions
Raltegravir + Truvada
Drug
Lead sponsor
David A Wohl, MD
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 8, 2026, 12:37 PM EDT
Completed Phase 3 Interventional Results available

Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)

NCT02345252
View directory record Official record
Conditions
HIV-1 Infection
Interventions
FTC/RPV/TAF, FTC/RPV/TDF Placebo, FTC/RPV/TDF, FTC/RPV/TAF Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
632 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
75
States / cities
Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 56 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2020 · Synced Oct 8, 2026, 12:37 PM EDT
Completed No phase listed Observational

Long-term Study on Anti-HBV Effect of Tenofovir and Resistance Surveillance in Asian-American Adult Patients

NCT01267162
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
Not listed
Lead sponsor
Medical Procare PLLC
Other
Eligibility
18 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
5
States / cities
Los Angeles, California • San Jose, California • Flushing, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2016 · Synced Oct 8, 2026, 12:37 PM EDT
Completed Phase 2 Interventional

Safety and Effectiveness of Adding PMPA Prodrug to an Anti-HIV Drug Combination to Treat HIV-Infected Patients

NCT00002415
View directory record Official record
Conditions
HIV Infections
Interventions
Tenofovir disoproxil fumarate
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
24
States / cities
Birmingham, Alabama • Phoenix, Arizona • Berkeley, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 8, 2026, 12:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

PrEPTECH Phase 2 Study of a PrEP Telehealth Intervention

NCT04902820
View directory record Official record
Conditions
Pre-Exposure Prophylaxis, HIV, Telemedicine
Interventions
PrEPTECH website, Online PrEP resource list
Other
Lead sponsor
ETR Associates
Other
Eligibility
15 Years to 27 Years · Male only
Enrollment
229 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Scotts Valley, California
Source: ClinicalTrials.gov public record
Updated Sep 11, 2023 · Synced Oct 8, 2026, 12:37 PM EDT
Terminated Phase 2 Interventional Results available

Phase IIB Pilot of Atazanavir + Raltegravir

NCT00768989
View directory record Official record
Conditions
HIV
Interventions
Atazanavir, Raltegravir, Ritonavir, Tenofovir/Emtricitabine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
9
States / cities
Phoenix, Arizona • New Haven, Connecticut • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2012 · Synced Oct 8, 2026, 12:37 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

NCT01309243
View directory record Official record
Conditions
HIV-1 Infection
Interventions
FTC/RPV/TDF, EFV/FTC/TDF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
799 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
83
States / cities
Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 59 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2015 · Synced Oct 8, 2026, 12:37 PM EDT
Active, not recruiting Phase 3 Interventional

Reducing Vertical Transmission of Hepatitis B in Africa

NCT04704024
View directory record Official record
Conditions
Hepatitis B Infection
Interventions
Tenofovir Disoproxil Fumarate, Lamivudine Oral Solution
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
16 Years to 50 Years · Female only
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 8, 2026, 12:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Quantification of Estradiol's Impact on Nucleotides in Cellular Populations of the Lower GI Tract

NCT03917420
View directory record Official record
Conditions
HIV/AIDS
Interventions
Tenofovir 300Mg Oral Tablet, Emtricitabine 200 MG
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 49 Years · Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 12, 2023 · Synced Oct 8, 2026, 12:37 PM EDT